Drug Profile
R 21
Alternative Names: Malaria virus-like particle vaccine - MultiMalVax; Matrix-M; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - Multimalvax; R-21; R21/Matrix-M; R21/Matrix-M adjuvanted malaria vaccine; R21/Matrix-M™ malaria vaccine; R21/MMLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator University of Oxford
- Developer GSK; Serum Institute of India; University of Oxford
- Class Antimalarials; Malaria vaccines; Parasitic vaccines; Subunit vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Falciparum malaria
Most Recent Events
- 20 Mar 2024 University of Oxford in collaboration with Bill and Melinda Gates Foundation and University Hospitals Bristol and Weston NHS Foundation initiates a phase I trial in Falciparum malaria (Prevention) in the UK (IM) (NCT06320535)
- 04 Feb 2024 Updated adverse event data from a phase III trial in Falciparum malaria released by Novavax
- 01 Feb 2024 Updated efficacy and adverse event data from a phase III trial in Falciparum malaria (In Children, In infants, Prevention) released by Serum Institute of India